Holen Sie sich die Stockscreener-App
3.09
0.65%
0.02
Handel nachbörslich:
3.05
-0.04
-1.29%
Schlusskurs vom Vortag:
$3.07
Offen:
$3.18
24-Stunden-Volumen:
1.42M
Relative Volume:
0.48
Marktkapitalisierung:
$343.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-167.86M
KGV:
-1.3473
EPS:
-2.2935
Netto-Cashflow:
$-132.31M
1W Leistung:
+15.30%
1M Leistung:
-2.52%
6M Leistung:
+28.22%
1J Leistung:
+197.12%
1-Tages-Spanne:
$3.04
$3.24
1-Wochen-Bereich:
$2.62
$3.24
52-Wochen-Spanne:
$1.01
$3.78
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.09 | 341.76M | 0 | -167.86M | -132.31M | -2.2935 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
H.C. Wainwright Remains a Buy on Cabaletta Bio (CABA) - The Globe and Mail
Cabaletta reports results, advances Rese-Cel autoimmune program - MSN
Cabaletta Reports Results, Advances Rese-Cel Autoimmune Program - MyChesCo
Aug Summary: Can Cabaletta Bio Inc disrupt its industryBuy Signal & Low Drawdown Investment Ideas - baoquankhu1.vn
Cabaletta Bio Inc (MEX:CABA) Stock Price, Trades & News - gurufocus.com
Cabaletta Bio Inc Stock Warning Signs - gurufocus.com
Cabaletta Bio, Inc. (CABA) Stock forecasts - uk.finance.yahoo.com
Cabaletta Bio, Inc. (CABA) Stock Forecasts - Yahoo! Finance Canada
Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright - MarketBeat
Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough - Streetwise Reports
HC Wainwright Weighs in on Cabaletta Bio Q1 Earnings - MarketBeat
CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
H.C. Wainwright reiterates Cabaletta Bio stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Cabaletta Bio stock rating at buy - Investing.com
Cabaletta Bio Inc. (CABA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Cabaletta Bio Incs ROIC above industry average2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Take Profit: What are Cabaletta Bio Incs recent SEC filings showingPortfolio Update Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Cabaletta Bio (NASDAQ:CABA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Cabaletta Bio, Inc.Common Stock (NQ: CABA - markets.financialcontent.com
This Biotech Stock Could Deliver 350% Returns in 12 Months - GuruFocus
Jefferies reiterates Cabaletta Bio stock rating on product profile By Investing.com - Investing.com India
Jefferies reiterates Cabaletta Bio stock rating on product profile - investing.com
Aug Retail: What is Cabaletta Bio Incs P E ratio telling usPortfolio Profit Report & Capital Efficient Trading Techniques - baoquankhu1.vn
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - marketbeat.com
Morgan Stanley Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00 - MarketBeat
Analyst Michael Ulz Lowers Price Target for Cabaletta Bio (CABA) to $13 | CABA Stock News - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $13 to $14 - Moomoo
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Guggenheim raises Cabaletta Bio stock price target on trial progress By Investing.com - Investing.com India
Jefferies reiterates Buy on Cabaletta Bio stock, $14 target By Investing.com - Investing.com Australia
Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley - TipRanks
Jefferies reiterates Buy on Cabaletta Bio stock, $14 target - Investing.com UK
William Blair reiterates Outperform on Cabaletta Bio stock By Investing.com - ca.investing.com
CABA Advances with Innovative Therapeutic Approaches - GuruFocus
Guggenheim raises Cabaletta Bio stock price target on trial progress - Investing.com
Cabaletta Bio Reports 2025 Financial Results, Highlights Progress on Rese-cel CAR-T Cell Therapy and Upcoming Clinical Milestones - minichart.com.sg
Jefferies Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cabaletta Bio 2024 Annual Report: Engineered T Cell Therapies, Competitive Landscape, and Intellectual Property Strategies for Autoimmune Diseases - Minichart
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.51%
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):